DD298054A5 - Stabilisierte leukocyten-interferone - Google Patents

Stabilisierte leukocyten-interferone Download PDF

Info

Publication number
DD298054A5
DD298054A5 DD90344228A DD34422890A DD298054A5 DD 298054 A5 DD298054 A5 DD 298054A5 DD 90344228 A DD90344228 A DD 90344228A DD 34422890 A DD34422890 A DD 34422890A DD 298054 A5 DD298054 A5 DD 298054A5
Authority
DD
German Democratic Republic
Prior art keywords
ifn
bile acid
acid
concentration
lactose
Prior art date
Application number
DD90344228A
Other languages
German (de)
English (en)
Inventor
Alberto Ferro
Original Assignee
�K@��������`��@�����@��k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by �K@��������`��@�����@��k�� filed Critical �K@��������`��@�����@��k��
Publication of DD298054A5 publication Critical patent/DD298054A5/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD90344228A 1989-09-28 1990-09-26 Stabilisierte leukocyten-interferone DD298054A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
DD298054A5 true DD298054A5 (de) 1992-02-06

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
DD90344228A DD298054A5 (de) 1989-09-28 1990-09-26 Stabilisierte leukocyten-interferone

Country Status (26)

Country Link
EP (1) EP0420049B1 (cs)
JP (1) JPH03130232A (cs)
KR (1) KR910005886A (cs)
CN (1) CN1050503A (cs)
AR (1) AR244551A1 (cs)
AT (1) ATE92334T1 (cs)
AU (1) AU636653B2 (cs)
CA (1) CA2024046A1 (cs)
CZ (1) CZ277712B6 (cs)
DD (1) DD298054A5 (cs)
DE (1) DE59002183D1 (cs)
FI (1) FI904756A7 (cs)
HU (1) HU205555B (cs)
IE (1) IE903479A1 (cs)
IL (1) IL95769A0 (cs)
IS (1) IS3631A7 (cs)
MC (1) MC2149A1 (cs)
MX (1) MX22522A (cs)
MY (1) MY106615A (cs)
NO (1) NO904218L (cs)
NZ (1) NZ235153A (cs)
PH (1) PH27531A (cs)
PT (1) PT95454A (cs)
RU (1) RU2008017C1 (cs)
YU (1) YU184090A (cs)
ZA (1) ZA907579B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
DE69715883T2 (de) * 1996-05-09 2003-07-31 Feronpatent Ltd., Gibraltar Stabilisierung von interferonen in wässriger lösung durch gummiarabikum
EP1007083A1 (en) * 1997-05-09 2000-06-14 Feronpatent Limited Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
DE102004048379A1 (de) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Federelement aus gesputterter Formgedächtnis-Legierung
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
DE3484374D1 (de) * 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
OA08269A (fr) * 1985-03-25 1987-10-30 Schering Corp Compositions stables à base d'interféron-gamma
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
NO904218D0 (no) 1990-09-27
PH27531A (en) 1993-08-18
PT95454A (pt) 1991-05-22
CS432890A3 (en) 1992-12-16
MX22522A (es) 1993-10-01
EP0420049A1 (de) 1991-04-03
AU636653B2 (en) 1993-05-06
CA2024046A1 (en) 1991-03-29
RU2008017C1 (ru) 1994-02-28
HU906021D0 (en) 1991-03-28
MY106615A (en) 1995-06-30
YU184090A (sh) 1992-09-07
IE903479A1 (en) 1991-04-10
ZA907579B (en) 1991-06-26
CZ277712B6 (en) 1993-03-17
CN1050503A (zh) 1991-04-10
DE59002183D1 (de) 1993-09-09
EP0420049B1 (de) 1993-08-04
IS3631A7 (is) 1991-03-29
FI904756A0 (fi) 1990-09-27
NZ235153A (en) 1993-03-26
HU205555B (en) 1992-05-28
AU6309890A (en) 1991-04-11
IL95769A0 (en) 1991-06-30
ATE92334T1 (de) 1993-08-15
NO904218L (no) 1991-04-02
HUT56284A (en) 1991-08-28
JPH03130232A (ja) 1991-06-04
AR244551A1 (es) 1993-11-30
KR910005886A (ko) 1991-04-27
MC2149A1 (fr) 1992-03-10
FI904756A7 (fi) 1991-03-29

Similar Documents

Publication Publication Date Title
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69620877T2 (de) Arzneimittelformulierungen für il-12
DE69329651T3 (de) Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält
DE68907124T2 (de) Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung.
DE69215355T2 (de) Stabilisierter Varizella-Lebendimpfstoff
DE2751717C2 (cs)
AT402259B (de) Verfahren zur herstellung eines stabilen pharmazeutischen präparats mit einem gehalt an granulozytkolonie stimulierendem faktor
DE69432179T3 (de) Eine formulierung des gerinnungsfaktors viii
DE69531204T2 (de) Formulierungen fuer faktor ix
EP0733702B1 (de) Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE3782828T2 (de) Interleukin-2-zusammensetzungen.
DE69630291T2 (de) Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält
DD298053A5 (de) Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE69029765T2 (de) Stabilisierung von hochgereinigten Proteinen
DE2827027C3 (de) Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen Verabreichung
DE69313444T2 (de) IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
DE4128319A1 (de) Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
DE2628914A1 (de) Thymusdruesenhormon, dessen herstellung und thymusdruesenhormon enthaltende praeparate
DD298054A5 (de) Stabilisierte leukocyten-interferone
DE60029614T2 (de) Formulierung einer wässrigen interferon-alpha lösung
DE69116565T2 (de) Verwendung gegen reaktive sauerstoffverbindungen schützender wirkstoffe
DE69426844T2 (de) Halbfeste Arzneimittel sowie Verfahren zu deren Herstellung
DE69101784T2 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor.
DE69836315T2 (de) Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee